Analyst Price Targets — QTTB
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| March 10, 2026 4:20 pm | Joseph Pantginis | H.C. Wainwright | $13.00 | $5.99 | StreetInsider | H.C. Wainwright Reiterates Buy Rating on Q32 Bio Inc. (QTTB): "2026 should be highlighted by key clinical data" |
| December 5, 2024 9:10 pm | Etzer Darout | BMO Capital | $64.00 | $23.69 | StreetInsider | BMO Capital Starts Q32 Bio Inc. (QTTB) at Outperform |
| October 16, 2024 6:22 am | Jay Olson | Oppenheimer | $80.00 | $48.47 | StreetInsider | Oppenheimer Reiterates Outperform Rating on Q32 Bio Inc. (QTTB) |
| September 11, 2024 5:27 am | Derek Archila | Wells Fargo | $95.00 | $50.61 | StreetInsider | Wells Fargo Starts Q32 Bio Inc. (QTTB) at Overweight |
| May 21, 2024 6:22 am | Thomas Smith | Leerink Partners | $54.00 | $30.20 | TheFly | Q32 Bio initiated with an Outperform at Leerink |
| April 10, 2024 4:02 pm | Jay Olson | Oppenheimer | $50.00 | $21.48 | StreetInsider | Oppenheimer Starts Q32 Bio Inc. (QTTB) at Outperform |
| April 2, 2024 5:02 am | Christopher Raymond | Raymond James | $45.00 | $18.00 | TheFly | Q32 Bio initiated with an Overweight at Piper Sandler |
| April 2, 2024 3:46 am | Allison Bratzel | Piper Sandler | $45.00 | $18.00 | StreetInsider | Piper Sandler Starts Q32 Bio Inc. (QTTB) at Overweight, 'we would be buyers here' |
Latest News for QTTB
QTTB, DXPE and TTEC made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on March 13th, 2026.
The mean of analysts' price targets for Q32 Bio (QTTB) points to a 103.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
TBLA, MCY, DXPE, CABO and QTTB have been added to the Zacks Rank #1 (Strong Buy) List on March 13th, 2026.
-- Completed enrollment in Part B of SIGNAL-AA Phase 2a clinical trial and increased trial size to 33 patients based on patient demand; 36-week topline data readout expected in mid-2026 -- -- Completed $10.5 million registered direct offering (RDO) -- -- Completed asset sale of Phase 2 complement inhibitor, ADX-097, to Akebia Therapeutics to further enable Company's strategic focus on advancing bempikibart for…
WALTHAM, Mass., Feb. 18, 2026 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA) and other autoimmune and inflammatory diseases, today announced that management will participate in a fireside chat at 2:00 p.m.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for QTTB.
U.S. House Trading
No House trades found for QTTB.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.